• 我要登录|
  • 免费注册
    |
  • 我的丁香通
    • 企业机构:
    • 成为企业机构
    • 个人用户:
    • 个人中心
  • 移动端
    移动端
丁香通 logo丁香实验_LOGO
搜实验

    大家都在搜

      大家都在搜

        0 人通过求购买到了急需的产品
        免费发布求购
        发布求购
        点赞
        收藏
        wx-share
        分享

        A High-Throughput Binding Assay for HERG

        互联网

        547
        The human homologue of the ether-a-go-go -related-gene (HERG) has been implicated in the “iatrogenic” long QT syndrome, with several products withdrawn from the market because of their interaction with this K + channel. The resultant impact on the pharmaceutical industry has been profound, with the need to assess whether compounds interact with HERG now at a much earlier stage in the drug development process. Electrophysiological assays for HERG have been used to evaluate drug candidates. However, these are time-consuming and expensive, and so a simple assay, suitable for general laboratory use, would be beneficial. The authors have established a radioligand binding assay that utilizes [3 H]dofetilide and membranes prepared from HEK293 cells stably expressing HERG. In assays performed at 25�C, [3 H]dofetilide (10 nM ) binding equilibrium was achieved by 30 min and was stable for at least 120 min. The affinity (K d ) of [3 H]dofetilide for HERG was 22.3 � 2.53 nM (n = 11; nH = 0.93 � 0.06) with a binding site density (B max ) of 8.92 � 0.94 pmol/mg protein. A range of class III antiarrhythmics was shown to inhibit [3 H]dofetilide binding to HERG-transfected membranes in a concentration-dependent manner. Moreover, noncardiac compounds associated with QT prolongation, such as pimozide, terfenadine, and haloperidol, also inhibit [3 H]dofetilide binding. This assay may therefore provide a simple method at an early stage in drug development to detect compounds that interact with HERG, potentially preventing QT prolongation in man.
        ad image
        提问
        扫一扫
        丁香实验小程序二维码
        实验小助手
        丁香实验公众号二维码
        扫码领资料
        反馈
        TOP
        打开小程序